论文部分内容阅读
目的 :探讨mdr1基因表达产物Pgp与突变 p5 3蛋白、EGFR是否存在相关性及其临床意义。方法 :采用免疫组化SP法 ,检测 10 7例原发性膀胱移行细胞癌中Pgp、突变 p5 3蛋白、EGFR表达情况。结果 :Pgp、突变p5 3蛋白、EGFR的阳性表达率分别为 6 3 .6 % ,72 .9%和 6 6 .4% ,三者的过表达均与膀胱癌的病理分级、分期和术后的复发有关 ;相关性研究显示Pgp表达与突变 p5 3蛋白和EGFR的表达密切相关 (P <0 .0 1)。结论 :Pgp、突变 p5 3蛋白和EGFR过表达不仅是判定原发性膀胱移行细胞癌恶性程度和预后的重要指标 ,而且提示原发性膀胱移行细胞癌中Pgp的表达可能与其他肿瘤一样 ,受到 p5 3和EGFR等的调控。
Objective: To investigate the relationship between the expression of mdr1 gene Pgp and the mutant p5 3 protein and EGFR and its clinical significance. Methods: Immunohistochemical SP method was used to detect the expression of Pgp, mutant p5 3 protein and EGFR in 107 cases of primary bladder transitional cell carcinoma. Results: The positive expression rates of Pgp, p35 protein and EGFR were 6.36%, 72.9% and 66.4% respectively. The overexpression of Pgp, EGFR and EGFR were correlated with the pathological grade, stage and postoperative The correlation study showed that the expression of Pgp was closely related to the expression of mutant p5 3 protein and EGFR (P <0.01). CONCLUSIONS: The overexpression of Pgp, p35 mutant protein and EGFR are not only the important indicators to judge the malignant degree and prognosis of primary bladder transitional cell carcinoma, but also suggest that the expression of Pgp in primary bladder transitional cell carcinoma may be similar to that of other tumors p5 3 and EGFR and other regulation.